Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Taiwan Bio Therapeutics (ROCO:6892) EV-to-EBIT Explanation
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Taiwan Bio Therapeutics's Enterprise Value for the quarter that ended in Jun. 2026 was NT$2,427.23 Mil.
Taiwan Bio Therapeutics's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$-188.78 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Taiwan Bio Therapeutics EV-to-EBIT Related Terms
Taiwan Bio Therapeutics EV-to-EBIT Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ROCO:6892 vs VRTX, REGN, MRNA: EV-to-EBIT Comparison
For the Biotechnology subindustry, Taiwan Bio Therapeutics's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Taiwan Bio Therapeutics EV-to-EBIT vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Taiwan Bio Therapeutics's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Taiwan Bio Therapeutics's EV-to-EBIT falls into.
Taiwan Bio Therapeutics's current Enterprise Value is NT$2,361.42 Mil.
Taiwan Bio Therapeutics's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$-188.78 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Taiwan Bio Therapeutics (ROCO:6892) has a EV-to-EBIT of -12.51 as of Sep. 09, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Taiwan Bio Therapeutics and its competitors. According to the industry distribution chart, Taiwan Bio Therapeutics ranks #999999 out of 365 companies in the Biotechnology industry.
Is Taiwan Bio Therapeutics' EV-to-EBIT too high?
Taiwan Bio Therapeutics' current EV-to-EBIT is -12.51. Based on the distribution chart, Taiwan Bio Therapeutics ranks #999999 out of 365 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Taiwan Bio Therapeutics has a GF Score™ of 30/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Taiwan Bio Therapeutics' EV-to-EBIT compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Taiwan Bio Therapeutics ranks #999999 out of 365 companies for EV-to-EBIT. This places Taiwan Bio Therapeutics in the lower half of its industry. The industry median EV-to-EBIT is 15.48. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Biotechnology company?
The median EV-to-EBIT among Biotechnology companies is 15.48, based on 365 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Taiwan Bio Therapeutics and its competitors. For the Biotechnology industry, the median EV-to-EBIT is 15.48 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Taiwan Bio Therapeutics's current EV-to-EBIT is -12.51. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Taiwan Bio Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Taiwan Bio Therapeutics (ROCO:6892) is currently considered Significantly Overvalued. The stock's GF Value™ is NT$14.36, compared to a current price of NT$26.10 — trading 81.8% above its estimated fair value. The current EV-to-EBIT is -12.51. Taiwan Bio Therapeutics' overall GF Score™ is 30/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Taiwan Bio Therapeutics (ROCO:6892), the current EV-to-EBIT is -12.51 as of Sep. 09, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Taiwan Bio Therapeutics (ROCO:6892) Overvalued in 2026?
Based on GuruFocus' analysis, Taiwan Bio Therapeutics stock appears to be overvalued.
The current stock price of NT$26.10 is trading 81.8% above its estimated GF Value™ of NT$14.36.
GuruFocus considers Taiwan Bio Therapeutics to be Significantly Overvalued.
Key valuation signals for ROCO:6892:
EV-to-EBIT: -12.51
GF Value™: NT$14.36 vs. price of NT$26.10 (81.8% above fair value)
No single metric tells the full story. See the ROCO:6892 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Taiwan Bio Therapeutics Inc is a regenerative medicine company specializing in the development of new genetically modified cell drugs. It is providing commissioned development and manufacturing (CDMO/CMO) services and inspection, analysis and development services for cellular medical products.
30GF Score
Get the complete analysis for ROCO:6892
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:6892 has been successfully added to your 
